Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes

IN BRIEF New treatments for type 2 diabetes are required to demonstrate cardiovascular safety in dedicated cardiovascular outcomes trials (CVOTs). This article reviews available evidence on cardiovascular, renal, and safety outcomes from CVOTs and real-world analyses of sodium–glucose cotransporter...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahady, Edward, Leahy, John L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2019
Materias:
Feature Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640890/
https://www.ncbi.nlm.nih.gov/pubmed/31371851
http://dx.doi.org/10.2337/cd18-0064
_version_ 1783436655734030336
author Shahady, Edward
Leahy, John L.
author_facet Shahady, Edward
Leahy, John L.
author_sort Shahady, Edward
collection PubMed
description IN BRIEF New treatments for type 2 diabetes are required to demonstrate cardiovascular safety in dedicated cardiovascular outcomes trials (CVOTs). This article reviews available evidence on cardiovascular, renal, and safety outcomes from CVOTs and real-world analyses of sodium–glucose cotransporter 2 inhibitors, along with considerations for their use in clinical practice.
format Online
Article
Text
id pubmed-6640890
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-66408902020-07-01 Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes Shahady, Edward Leahy, John L. Clin Diabetes Feature Articles IN BRIEF New treatments for type 2 diabetes are required to demonstrate cardiovascular safety in dedicated cardiovascular outcomes trials (CVOTs). This article reviews available evidence on cardiovascular, renal, and safety outcomes from CVOTs and real-world analyses of sodium–glucose cotransporter 2 inhibitors, along with considerations for their use in clinical practice. American Diabetes Association 2019-07 /pmc/articles/PMC6640890/ /pubmed/31371851 http://dx.doi.org/10.2337/cd18-0064 Text en © 2018 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0 for details.
spellingShingle Feature Articles
Shahady, Edward
Leahy, John L.
Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
title Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
title_full Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
title_fullStr Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
title_full_unstemmed Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
title_short Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
title_sort sodium–glucose cotransporter 2 inhibitor protection against adverse cardiovascular and renal outcomes in patients with type 2 diabetes
topic Feature Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640890/
https://www.ncbi.nlm.nih.gov/pubmed/31371851
http://dx.doi.org/10.2337/cd18-0064
work_keys_str_mv AT shahadyedward sodiumglucosecotransporter2inhibitorprotectionagainstadversecardiovascularandrenaloutcomesinpatientswithtype2diabetes
AT leahyjohnl sodiumglucosecotransporter2inhibitorprotectionagainstadversecardiovascularandrenaloutcomesinpatientswithtype2diabetes

Ejemplares similares